Lukas Biomedical (ROCO:6814) Beneish M-Score: -2.66 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
66 GF Score
Price NT$24.65
GF Value NT$21.77
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical Beneish M-Score?

Lukas Biomedical ROCO:6814 +4.45% 66 Beneish M-Score is -2.66 as of Jul. 21, 2026. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.77 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 825 Biotechnology companies, Lukas Biomedical ranks better than 63.03% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Lukas Biomedical's Beneish M-Score or its related term are showing as below:

ROCO:6814' s Beneish M-Score Range Over the Past 10 Years
Min: -2.95   Med: -2.91   Max: -2.66
Current: -2.66

During the past 8 years, the highest Beneish M-Score of Lukas Biomedical was -2.66. The lowest was -2.95. And the median was -2.91.


Lukas Biomedical Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Beneish M-Score Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.92 -2.93 -2.95 -2.83 -2.66

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.95 0.00 -2.83 0.00 -2.66

ROCO:6814 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Lukas Biomedical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lukas Biomedical Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's Beneish M-Score falls into.


ROCO:6814
66GF Score
Lukas Biomedical Inc ROCO:6814
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lukas Biomedical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2585+0.528 * 0.9916+0.404 * 1.0685+0.892 * 0.9456+0.115 * 1.0277
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0185+4.679 * -0.056717-0.327 * 1.3887
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$11.5 Mil.
Revenue was NT$179.5 Mil.
Gross Profit was NT$107.9 Mil.
Total Current Assets was NT$92.3 Mil.
Total Assets was NT$426.8 Mil.
Property, Plant and Equipment(Net PPE) was NT$50.5 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$25.0 Mil.
Selling, General, & Admin. Expense(SGA) was NT$106.2 Mil.
Total Current Liabilities was NT$114.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$68.2 Mil.
Net Income was NT$-85.6 Mil.
Gross Profit was NT$0.0 Mil.
Cash Flow from Operations was NT$-61.4 Mil.
Total Receivables was NT$9.7 Mil.
Revenue was NT$189.8 Mil.
Gross Profit was NT$113.1 Mil.
Total Current Assets was NT$124.5 Mil.
Total Assets was NT$476.5 Mil.
Property, Plant and Equipment(Net PPE) was NT$55.3 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$28.6 Mil.
Selling, General, & Admin. Expense(SGA) was NT$110.3 Mil.
Total Current Liabilities was NT$56.9 Mil.
Long-Term Debt & Capital Lease Obligation was NT$90.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11.519 / 179.493) / (9.68 / 189.828)
=0.064175 / 0.050994
=1.2585

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(113.116 / 189.828) / (107.867 / 179.493)
=0.595887 / 0.600954
=0.9916

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (92.326 + 50.492) / 426.803) / (1 - (124.496 + 55.269) / 476.504)
=0.665377 / 0.622742
=1.0685

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=179.493 / 189.828
=0.9456

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(28.555 / (28.555 + 55.269)) / (25.035 / (25.035 + 50.492))
=0.340654 / 0.331471
=1.0277

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(106.238 / 179.493) / (110.319 / 189.828)
=0.591878 / 0.581152
=1.0185

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((68.226 + 114.811) / 426.803) / ((90.232 + 56.926) / 476.504)
=0.428856 / 0.308828
=1.3887

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-85.633 - 0 - -61.426) / 426.803
=-0.056717

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lukas Biomedical has a M-score of -2.66 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.66 mean?
Lukas Biomedical (ROCO:6814) has a Beneish M-Score of -2.66 as of Jul. 21, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lukas Biomedical and its competitors. According to the industry distribution chart, Lukas Biomedical ranks #305 out of 825 companies in the Biotechnology industry, placing it in the top 37%.
Is Lukas Biomedical's Beneish M-Score too high?
Lukas Biomedical's current Beneish M-Score is -2.66. Based on the distribution chart, Lukas Biomedical ranks #305 out of 825 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #305 out of 825 companies for Beneish M-Score. This puts Lukas Biomedical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lukas Biomedical and its competitors. Lukas Biomedical's current Beneish M-Score is -2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.65 — trading 13.2% above its estimated fair value. The current Beneish M-Score is -2.66. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Beneish M-Score is -2.66 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$24.65 is trading 13.2% above its estimated GF Value™ of NT$21.77. GuruFocus considers Lukas Biomedical to be Modestly Overvalued.

Key valuation signals for ROCO:6814:

  • Beneish M-Score: -2.66
  • GF Value™: NT$21.77 vs. price of NT$24.65 (13.2% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score

Get the complete analysis for ROCO:6814

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.65
Price
NT$21.77
GF Value